Pethema Foundation
Clinical trials sponsored by Pethema Foundation, explained in plain language.
-
New drug combo shows promise in AML patients without FLT3 mutation
Disease control CompletedThis study tested whether adding the drug quizartinib to standard chemotherapy helps adults with a common type of acute myeloid leukemia (AML) that lacks a specific FLT3 mutation. About 273 newly diagnosed patients aged 18 to 70 took part. The main goal was to see if the combinat…
Phase: PHASE2 • Sponsor: PETHEMA Foundation • Aim: Disease control
Last updated May 26, 2026 09:28 UTC
-
New Triple-Drug attack shows promise for older AML patients
Disease control CompletedThis study tested a combination of three drugs (low-dose cytarabine or azacitidine, plus venetoclax and quizartinib) in 113 adults aged 60 and older with newly diagnosed acute myeloid leukemia (AML) who could not receive standard chemotherapy. The goal was to quickly control the …
Phase: PHASE1, PHASE2 • Sponsor: PETHEMA Foundation • Aim: Disease control
Last updated May 22, 2026 13:50 UTC